Abbott launches updated stroke device
This article was originally published in The Gray Sheet
Executive Summary
Firm announces CE mark approval and European launch of its Emboshield PRO embolic protection system on Sept. 13. The next-generation device is more radiopaque than its predecessor, providing better X-ray visibility, Abbott says. Its small size and enhanced profile position the device as a new option for tortuous vessels, according to the firm. Separately, on Sept. 12 the firm reported an expansion of its manufacturing facility in Ireland to ramp up production of the Xience V drug-eluting stent, expected to debut in October (1"The Gray Sheet" Sept. 11, 2006, p. 5)...
You may also be interested in...
On Eve Of European Launch, Abbott’s Xience V Outperforms Taxus
Abbott is trumpeting the latest findings about its Xience V drug-eluting stent in preparation for next month's European launch
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.